Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Inorganic Fiber-Polymer Composite-Based Quasi-Solid Electrolyte for High-Performance Electrochromic Devices.

ACS nano·2026

Same author

Correction: RNA‑binding protein CCDC137 activates AKT signaling and promotes hepatocellular carcinoma through a novel non‑canonical role of DGCR8 in mRNA localization.

Journal of experimental & clinical cancer research : CR·2025

Same author

Noninvasive evaluation of treatment-related protein expression status in advanced gastric cancer using dynamic nomograms with dual-energy CT: a multicenter study.

European radiology·2025

Same author

Dynamic AI Ultrasound-Assisted Diagnosis System to Reduce Unnecessary Fine Needle Aspiration of Thyroid Nodules.

Journal of clinical ultrasound : JCU·2025

Same author

A Pan-Inhibitor of Phosphate Transporters AP306 in Hemodialysis Patients.

Kidney international reports·2025

Same author

CCDC80 Protects against Aortic Dissection and Rupture by Maintaining the Contractile Smooth Muscle Cell Phenotype.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025

Search research articles

Related Experiment Video

Updated: May 12, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Angelicone Ameliorates Ulcerative Colitis in Mice via Modulating Gut Microbiota.

Chengwei Ruan¹, Weiwei Gao¹, Guoguo Wang²

¹Department of Anal-Rectal, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

|March 24, 2025

Summary

Angelicone, derived from Angelica sinensis, shows promise in treating ulcerative colitis (UC) by improving gut microbiota and reducing inflammation. This compound helps restore intestinal barrier integrity and microbial balance in UC models.

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Related Experiment Videos

Last Updated: May 12, 2026

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

Area of Science:

Gastroenterology
Pharmacology
Microbiology

Background:

Ulcerative colitis (UC) is a chronic inflammatory gastrointestinal disorder.
Angelicone, from Angelica sinensis, is a potential therapeutic agent for UC.
The role of angelicone in UC, especially concerning gut microbiota, is not well understood.

Purpose of the Study:

To investigate the effects of angelicone on gut microbiota in a mouse model of UC.
To explore the therapeutic mechanisms of angelicone in UC management.

Main Methods:

Ulcerative colitis was induced in mice using 3% dextran sodium sulfate (DSS).
Gut microbiota composition was analyzed using 16S rRNA sequencing.
Clinical, histological, and molecular parameters were assessed following angelicone treatment.

Main Results:

Angelicone significantly improved clinical symptoms, reduced colonic damage, and decreased inflammatory cytokine levels in UC mice.
Treatment with angelicone restored the integrity of the intestinal epithelial barrier.
Angelicone modulated the gut microbiota, increasing overall abundance and partially restoring the balance of key phyla (Proteobacteria, Firmicutes, Bacteroidetes).

Conclusions:

Angelicone demonstrates significant therapeutic potential for ulcerative colitis.
The beneficial effects of angelicone are associated with the modulation of gut microbiota composition and function.
This study provides new insights into the intervention mechanisms of angelicone in UC treatment.